BioSpace News Archive

Company intends to develop and extend its diverse pipeline of therapies for cancer and immune diseases, beginning with four entities

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the BofA Securities 2021 Health Care Conference on Wednesday, May 12, 2021 at 2:00 p.m. ET.

Total Company Net Revenue of $41 Million, an Increase of 7% versus Prior Year Net Income of $5.2 Million, EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today

Use of outpatient mental health services up nearly 20%, anxiety and depression top list of telehealth diagnoses Spending on substance use disorder treatment increased 10%

DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that Rick Anderson, President and General Manager of North America, will participate in the Vatican’s Pontifical Council for Culture and The Cura Foundation’s Fifth International Vatican Conference.

ZS and Seven Bridges today announced a partnership that will combine ZS’s expertise in biomedical research services and data science with Seven Bridges technology platform enabling multi-omics analytics, spanning the translational to clinical continuum

Lotus Pharmaceuticals, Inc President Georgene Rivers announced that Lotus Pharmaceuticals, Inc. has entered into a Land Development Deal.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced it will host a conference call on Wednesday May 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2021, in addition to providing a business update.

TwinStrand’s transformational improvements in DNA sequencing accuracy deliver 10,000x greater sensitivity, making it a crucial tool for genomic research and medicine Financing was led by Section 32 partner Michael Pellini, MD who has also joined the company’s Board of Directors

First-ever head-to-head study in chronic dry eye disease, comparing SURF-100 against leading on-market competitors lifitegrast ophthalmic solution 5% and cyclosporine ophthalmic emulsion 0.05%